Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
University of Alabama at Birmingham · Velocity Clinical Research (United States) · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
660
total citations
- FWCI
- 118.12
- Percentile
- 100%
- References
- 36
Citations per year
Authors
96Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Type 2 diabetes
- Discontinuation
- Body mass index
- Population
- Internal medicine
- Weight loss
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.